ECSP034932A - Derivados de tetrahidroquinolina - Google Patents
Derivados de tetrahidroquinolinaInfo
- Publication number
- ECSP034932A ECSP034932A EC2003004932A ECSP034932A ECSP034932A EC SP034932 A ECSP034932 A EC SP034932A EC 2003004932 A EC2003004932 A EC 2003004932A EC SP034932 A ECSP034932 A EC SP034932A EC SP034932 A ECSP034932 A EC SP034932A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- heterocycloalkyl
- nhc
- heteroaryl
- cycloalkyl
- Prior art date
Links
- 150000003530 tetrahydroquinolines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- -1 nitro, hydroxyl Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01202531 | 2001-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034932A true ECSP034932A (es) | 2004-02-26 |
Family
ID=8180574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004932A ECSP034932A (es) | 2001-07-02 | 2003-12-30 | Derivados de tetrahidroquinolina |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8058441B2 (enExample) |
| EP (1) | EP1406628B1 (enExample) |
| JP (1) | JP4523273B2 (enExample) |
| KR (1) | KR100908468B1 (enExample) |
| CN (1) | CN1261099C (enExample) |
| AR (1) | AR034669A1 (enExample) |
| AT (1) | ATE319451T1 (enExample) |
| AU (1) | AU2002317848B2 (enExample) |
| BR (1) | BR0210645A (enExample) |
| CA (1) | CA2452606C (enExample) |
| CY (1) | CY1106087T1 (enExample) |
| CZ (1) | CZ20042A3 (enExample) |
| DE (1) | DE60209734T2 (enExample) |
| DK (1) | DK1406628T3 (enExample) |
| EC (1) | ECSP034932A (enExample) |
| ES (1) | ES2260458T3 (enExample) |
| HR (1) | HRP20031080A2 (enExample) |
| HU (1) | HUP0400390A2 (enExample) |
| IL (1) | IL159288A0 (enExample) |
| IS (1) | IS2418B (enExample) |
| MX (1) | MXPA03011908A (enExample) |
| NO (1) | NO325516B1 (enExample) |
| NZ (1) | NZ530198A (enExample) |
| PE (1) | PE20030273A1 (enExample) |
| PL (1) | PL367638A1 (enExample) |
| PT (1) | PT1406628E (enExample) |
| RU (1) | RU2347570C2 (enExample) |
| SA (1) | SA02230260B1 (enExample) |
| SK (1) | SK286759B6 (enExample) |
| WO (1) | WO2003004028A1 (enExample) |
| ZA (1) | ZA200309921B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2452606C (en) | 2001-07-02 | 2011-09-13 | Akzo Nobel N.V. | Tetrahydroquinoline derivatives |
| ATE416168T1 (de) * | 2002-02-15 | 2008-12-15 | Glaxo Group Ltd | Modulatoren des vanilloidrezeptors |
| FR2836620B1 (fr) * | 2002-02-28 | 2004-04-16 | Snecma Services | Instrument de projection thermique |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| TWI322012B (en) * | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| TWI306855B (en) * | 2002-12-20 | 2009-03-01 | Organon Nv | Tetrahydroquinoline derivatives |
| SE0300480D0 (sv) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| MXPA05012705A (es) * | 2003-05-29 | 2006-02-08 | Astrazeneca Ab | Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral. |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| EP1644042A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| KR100554155B1 (ko) * | 2003-06-09 | 2006-02-22 | 학교법인 포항공과대학교 | 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법 |
| SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| US7691848B2 (en) | 2005-03-02 | 2010-04-06 | Wyeth | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists |
| CN101171234B (zh) | 2005-05-04 | 2011-11-16 | 欧加农股份有限公司 | 二氢吡啶衍生物 |
| UA92007C2 (ru) | 2005-05-04 | 2010-09-27 | Н.В. Органон | Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности |
| UA92009C2 (ru) * | 2005-05-04 | 2010-09-27 | Н.В. Органон | Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия |
| UA92008C2 (en) * | 2005-05-04 | 2010-09-27 | Н.В. Органон | 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY |
| EP1879898A2 (en) | 2005-05-12 | 2008-01-23 | Wyeth a Corporation of the State of Delaware | Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (fsh-r) antagonists |
| CN101208342A (zh) | 2005-06-09 | 2008-06-25 | 惠氏公司 | 作为促卵泡激素受体拮抗剂的吡咯并苯并二氮杂䓬吡啶羧酰胺和衍生物 |
| EP1912970A2 (en) * | 2005-08-10 | 2008-04-23 | Bayer Schering Pharma Aktiengesellschaft | Acyltryptophanols for fertility control |
| US20070060573A1 (en) * | 2005-08-10 | 2007-03-15 | Lars Wortmann | Acyltryptophanols |
| WO2008071453A1 (en) * | 2006-12-13 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | 1,2-diarylacetylene derivatives of acyltryptophanols |
| EP1932831A1 (en) * | 2006-12-13 | 2008-06-18 | Bayer Schering Pharma Aktiengesellschaft | 1,2-Diarylacetylene Derivatives of Acyltryptophanols |
| TWI410422B (zh) | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | 縮合四氫喹啉衍生物及其醫藥用途 |
| TW200848021A (en) | 2007-03-06 | 2008-12-16 | Wyeth Corp | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
| RU2460727C2 (ru) * | 2007-03-22 | 2012-09-10 | Астразенека Аб | Хинолиновые производные для лечения воспалительных заболеваний |
| TW200918058A (en) * | 2007-08-31 | 2009-05-01 | Organon Nv | TSH receptor antagonizing tetrahydroquinoline compounds |
| PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
| RU2359684C1 (ru) * | 2008-01-23 | 2009-06-27 | Закрытое акционерное общество "СКАЙ ЛТД" | Способ лечения эндометриоза |
| TW200944523A (en) | 2008-02-08 | 2009-11-01 | Organon Nv | (Dihydro)pyrrolo[2,1-a]isoquinolines |
| US20100061976A1 (en) * | 2008-07-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
| TWI461426B (zh) * | 2009-05-27 | 2014-11-21 | Merck Sharp & Dohme | （二氫）咪唑並異〔５，１－ａ〕喹啉類 |
| US8071587B2 (en) | 2009-05-27 | 2011-12-06 | N. V. Organon | (Dihydro)imidazoiso[5,1-A]quinolines |
| TW201116531A (en) | 2009-07-29 | 2011-05-16 | Organon Nv | Ring-annulated dihydropyrrolo[2,1-a]isoquinolines |
| US8431564B2 (en) | 2009-07-29 | 2013-04-30 | Merck Sharp & Dohme B.V. | Ring-annulated dihydropyrrolo[2,1-α]isoquinolines |
| TW201116515A (en) | 2009-07-31 | 2011-05-16 | Organon Nv | Dihydrobenzoindazoles |
| ES2553771T3 (es) * | 2010-10-08 | 2015-12-11 | Nivalis Therapeutics, Inc. | Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa |
| US8546427B2 (en) * | 2010-10-20 | 2013-10-01 | Hoffmann-La Roche Inc. | Tetrahydroquinoline derivatives |
| WO2016018553A1 (en) * | 2014-07-30 | 2016-02-04 | Henkel IP & Holding GmbH | Cure accelerators for anaerobic curable compositions |
| US12275729B2 (en) | 2017-11-01 | 2025-04-15 | Merck Sharp & Dohme Llc | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| CN119954701B (zh) * | 2024-06-18 | 2026-06-16 | 青岛润农化工有限公司 | 一种丁醚脲的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2686182A (en) | 1950-12-07 | 1954-08-10 | Basf Ag | O-hydroxy-dihydro-quinoline carboxylic acids |
| DE19975054I2 (de) | 1987-08-08 | 2000-04-13 | Akzo Nobel Nv | Kontrazeptives Implantat |
| AU717251B2 (en) * | 1994-12-22 | 2000-03-23 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| WO2000008015A2 (en) * | 1998-08-07 | 2000-02-17 | Applied Research Systems Ars Holding N.V. | Fsh mimetics for the treatment of infertility |
| JP2000143636A (ja) * | 1998-09-02 | 2000-05-26 | Sumitomo Pharmaceut Co Ltd | アミノ誘導体 |
| US6200963B1 (en) * | 1999-03-31 | 2001-03-13 | American Home Products Corporation | Aryl sulfonic acids as FSH antagonists |
| CA2452606C (en) | 2001-07-02 | 2011-09-13 | Akzo Nobel N.V. | Tetrahydroquinoline derivatives |
| TWI306855B (en) | 2002-12-20 | 2009-03-01 | Organon Nv | Tetrahydroquinoline derivatives |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
-
2002
- 2002-06-25 CA CA2452606A patent/CA2452606C/en not_active Expired - Fee Related
- 2002-06-25 PT PT02747437T patent/PT1406628E/pt unknown
- 2002-06-25 NZ NZ530198A patent/NZ530198A/en not_active IP Right Cessation
- 2002-06-25 CN CNB02813334XA patent/CN1261099C/zh not_active Expired - Fee Related
- 2002-06-25 EP EP02747437A patent/EP1406628B1/en not_active Expired - Lifetime
- 2002-06-25 IL IL15928802A patent/IL159288A0/xx not_active IP Right Cessation
- 2002-06-25 CZ CZ20042A patent/CZ20042A3/cs unknown
- 2002-06-25 DE DE60209734T patent/DE60209734T2/de not_active Expired - Lifetime
- 2002-06-25 SK SK1634-2003A patent/SK286759B6/sk not_active IP Right Cessation
- 2002-06-25 BR BR0210645-0A patent/BR0210645A/pt not_active IP Right Cessation
- 2002-06-25 WO PCT/EP2002/007053 patent/WO2003004028A1/en not_active Ceased
- 2002-06-25 HR HR20031080A patent/HRP20031080A2/hr not_active Application Discontinuation
- 2002-06-25 DK DK02747437T patent/DK1406628T3/da active
- 2002-06-25 JP JP2003510039A patent/JP4523273B2/ja not_active Expired - Fee Related
- 2002-06-25 AU AU2002317848A patent/AU2002317848B2/en not_active Ceased
- 2002-06-25 PL PL02367638A patent/PL367638A1/xx unknown
- 2002-06-25 MX MXPA03011908A patent/MXPA03011908A/es active IP Right Grant
- 2002-06-25 US US10/482,707 patent/US8058441B2/en not_active Expired - Fee Related
- 2002-06-25 AT AT02747437T patent/ATE319451T1/de not_active IP Right Cessation
- 2002-06-25 HU HU0400390A patent/HUP0400390A2/hu unknown
- 2002-06-25 KR KR1020037017088A patent/KR100908468B1/ko not_active Expired - Fee Related
- 2002-06-25 RU RU2004102693/15A patent/RU2347570C2/ru not_active IP Right Cessation
- 2002-06-25 ES ES02747437T patent/ES2260458T3/es not_active Expired - Lifetime
- 2002-06-27 PE PE2002000581A patent/PE20030273A1/es not_active Application Discontinuation
- 2002-07-01 AR ARP020102468A patent/AR034669A1/es unknown
- 2002-08-26 SA SA02230260A patent/SA02230260B1/ar unknown
-
2003
- 2003-12-11 IS IS7071A patent/IS2418B/is unknown
- 2003-12-22 NO NO20035763A patent/NO325516B1/no not_active IP Right Cessation
- 2003-12-22 ZA ZA200309921A patent/ZA200309921B/en unknown
- 2003-12-30 EC EC2003004932A patent/ECSP034932A/es unknown
-
2006
- 2006-05-16 CY CY20061100628T patent/CY1106087T1/el unknown
-
2011
- 2011-10-07 US US13/268,214 patent/US8258293B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106087T1 (el) | Παραγωγα τετραϋδροκινολινης | |
| AR043938A1 (es) | Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| CO5200848A1 (es) | Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| BR0208678A (pt) | Composto, composição farmacêutica, uso de um composto | |
| CO5550462A2 (es) | Derivados de dolastatina 10 | |
| AR004735A1 (es) | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. | |
| AR088808A2 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR087241A2 (es) | Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica | |
| AR043436A1 (es) | Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6 | |
| YU18999A (sh) | Supstituisani tricikli | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| AR035817A1 (es) | Compuestos de azabiciclico sustituidos que actuan sobre el receptor alfa7 nicotinico de la acetilcolina o donde existe un deficit en la formacion de ventanas sensoriales y su uso en la preparacion de medicamentos | |
| AR046313A1 (es) | Compuesto de 2-cianopirrolidincarboxamida, un metodo para su obtencion y su empleo en composiciones farmaceuticas y en medicamentos con actividad inhibitoria de la dipeptidil peptidasa-iv (dpp-iv). | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| AR021355A1 (es) | Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento | |
| ECSP045078A (es) | Tiofen- y tiazolsulfonamidas como agentes antineoplásicos | |
| AR036327A1 (es) | Compuestos derivados del cromano para uso terapeutico, composicion farmaceutica, uso de estos compuestos para la preparacion de medicamentos para tratar migrana, compuestos relacionados, y procesos para preparar esos compuestos relacionados | |
| AR029400A1 (es) | Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende | |
| AR039651A1 (es) | Derivados de isoquinolina | |
| AR046793A1 (es) | Derivados de pirazol, antagonistas del receptor de la orexina | |
| BR0317514A (pt) | Derivado de tetraidroquinolina, composição farmacêutica, e, uso do derivado de tetraidroquinolina |